Blog - Latest News

10 Reasons Why We Remain Confidently Short Ampio Pharmaceuticals

Although we started shorting Ampio (AMPE) in the high $3s, we continue to hold our short position. We don’t believe that Ampio’s osteoarthritis drug, Ampion, will ever get approved, and the company will likely be required by the FDA to do another trial to seek approval. Their next trial will likely have the same result as their previous Ampion trial, which failed to show improvement over saline injections.   If our thesis is true, the stock will go sub $2 in short orde